SORRENTO THERAPEUTICS INC - SRNE STOCK NEWS

Sorrento Therapeutics (Nasdaq: SRNE) announced an upcoming COVID-19 Pipeline Update call on October 13, 2020, at 16:30 ET. The call will include discussions on their therapeutic pipeline, featuring candidates like STI-1499 (neutralizing antibody) and STI-5656 (abivertinib). Management will also cover diagnostics and therapeutic discoveries. Key participants include Dr. Henry Ji and Dr. Mark Brunswick. The event will be accessible for 30 days on Sorrento's website, allowing for public engagement through questions during the webcast.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE) has announced the discovery of Salicyn-30, a small molecule that achieved a 3-4 log reduction in SARS-CoV-2 viral load during preclinical studies. This compound may serve as a standalone therapy or function synergistically with Sorrento's existing neutralizing antibodies, STI-1499 and STI-2020. Salicyn-30 is orally bioavailable and displays a novel inhibition mechanism against the virus. Sorrento's drug repurposing approach aims to efficiently develop effective COVID-19 treatments as part of their broader therapy pipeline.

Sorrento Therapeutics (SRNE) announces the discovery of Salicyn-30, a small molecule showing a significant 3-4 log reduction in SARS-CoV-2 viral load in preclinical studies. This molecule may serve as a standalone oral therapy and in combination with existing neutralizing antibodies, STI-1499 and STI-2020. Salicyn-30's unique mechanism offers potential benefits in multi-modal therapy approaches for COVID-19. Sorrento continues to develop strategies targeting COVID-19 through drug repurposing, aiming to enhance treatment options across the disease continuum.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE) announced that Scilex's ZTlido® net sales for Q3 2020 are approximately $7.2 million, a 26% increase from Q2 2020. The Phase 3 trial for SP-102, aimed at treating lumbosacral radicular pain, is over 90% enrolled, with top-line data expected by Q2 2021. SP-102 could become the first FDA-approved epidural steroid for sciatica, addressing a significant unmet medical need.

Sorrento Therapeutics (Nasdaq: SRNE) announced a R&D Day conference call on October 13, 2020, focusing on its multi-modal approach to COVID-19.

Key topics will include pipeline updates, challenges, and future growth drivers in the COVID-19 sector. The event will feature executives such as Dr. Henry Ji and Dr. Mike Royal, discussing clinical and pre-clinical stage products like STI-1499 and STI-5656.

Sorrento aims to provide insights into its comprehensive pipeline, emphasizing its ongoing commitment to combating COVID-19.

Sorrento Therapeutics (SRNE) announced results from a Phase 1b study evaluating the safety and efficacy of epidural resiniferatoxin (RTX) for advanced cancer pain. Seventeen subjects received varying doses of RTX, with 64.7% reporting over 30% pain reduction. No dose-limiting toxicities were observed, and the treatment was well-tolerated. Preliminary findings support the advancement to a Phase 3 trial, which Sorrento plans to submit for FDA approval soon. The results highlight RTX as a promising non-opioid option for patients with intractable pain.

Sorrento Therapeutics (Nasdaq: SRNE) announced FDA approval to proceed with patient enrollment for its Phase 1 clinical trial of STI-1499 (COVI-GUARD™) in hospitalized COVID-19 patients. The company anticipates rapid enrollment and aims to submit for Emergency Use Authorization (EUA) by year-end. STI-1499 has shown a 100% neutralizing effect against SARS-CoV-2 in preclinical studies, including variants like D614G. Sorrento is preparing to manufacture 50,000 doses in anticipation of the EUA, demonstrating potential for a rapid clinical response in the ongoing pandemic.

Sorrento Therapeutics (SRNE) has entered an exclusive license agreement with Mayo Clinic for a novel technology platform that generates diverse antibody-drug-nanoparticle complexes (ADNICs) aimed at treating various cancers. This platform addresses limitations of existing antibody-drug conjugates (ADCs) by improving drug delivery efficiency and reducing manufacturing costs. Preliminary clinical trials show promising results, with potential expansion planned. The technology is backed by a strong patent portfolio, and Sorrento aims to develop multiple next-generation product candidates for cancer and COVID-19 treatments.

Sorrento Therapeutics has acquired SmartPharm Therapeutics, a company focusing on gene-encoded protein therapeutics, for $19.4 million. The acquisition, completed on September 1, 2020, aims to leverage SmartPharm's gene delivery platforms alongside Sorrento's G-MAB™ antibody library to develop cost-effective antibody therapies for COVID-19 and rare diseases. This integration is expected to enhance accessibility and affordability in antibody treatment, with potential applications across various conditions. SmartPharm's team will remain in place to facilitate integration.